Prelude Therapeutics INC 8-K filings

Prelude Therapeutics announced its second quarter 2026 financial results, highlighting progress in its oncology pipeline and a cash runway extending into Q2 2028.

Prelude Therapeutics Incorporated announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Prelude Therapeutics reported Q1 2026 financial results, highlighting progress in its PRT12396 and PRT13722 programs, and extended cash runway into Q2 2028.

Prelude Therapeutics announced new preclinical data for its lead candidate, PRT13722, a selective KAT6A degrader, showing potential for differentiated efficacy and safety in HR+/HER2- breast cancer.

Prelude Therapeutics Incorporated announced the appointment of Dr. Charles Morris as its new Chief Medical Officer, effective April 20, 2026, bringing extensive oncology drug development experience to the company.

Prelude Therapeutics Inc. has filed a prospectus supplement to offer and sell up to an additional $25.0 million of its common stock through an at-the-market facility.

Prelude Therapeutics announced FDA clearance for its Investigational New Drug Application for PRT12396, initiating a Phase 1 study for myeloproliferative neoplasms.

Prelude Therapeutics announces significant progress in its oncology pipeline, including two lead programs advancing to clinical trials and a strategic option agreement with Incyte.

Prelude Therapeutics announced its third-quarter 2025 financial results, showcasing reduced net loss and significant progress in its oncology pipeline, including two programs nearing IND filings.

Prelude Therapeutics announced a strategic shift, prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing a significant option agreement with Incyte.

Prelude Therapeutics announced the appointment of Katina Dorton to its Board of Directors and as Audit Committee Chair, succeeding Mardi Dier.

Prelude Therapeutics Incorporated announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed non-compliance matter.

Prelude Therapeutics reports Q2 2025 financial results, pauses IV SMARCA2 degrader PRT3789 to focus on oral PRT7732, and extends cash runway into Q2 2026.

Prelude Therapeutics Incorporated announced the appointment of Dr. Paul Scherer to its Board of Directors and the successful adoption of all proposals at its 2025 Annual Meeting of Stockholders, including the election of two Class II Directors, ratification of auditors, and an increase in authorized non-voting common stock.

Prelude Therapeutics announces Q1 2025 financial results, highlighting progress in clinical trials for PRT3789 and PRT7732, and anticipates data updates in the second half of 2025.

Prelude Therapeutics presents new preclinical data at the AACR Annual Meeting for its selective SMARCA2 degrader PRT3789 and KAT6A degraders, showcasing potential for improved cancer treatment.

Prelude Therapeutics received a notice from Nasdaq for failing to maintain a minimum stock price of $1.00, putting its listing at risk.

Prelude Therapeutics announces its full year 2024 financial results, highlighting clinical progress with SMARCA2 degraders and a cash runway into the second quarter of 2026.

Prelude Therapeutics names Bryant D. Lim as its permanent Chief Financial Officer, solidifying his role after serving as interim CFO.

Prelude Therapeutics reported encouraging interim results from a Phase 1 trial of PRT2527, a CDK9 inhibitor, showing activity in relapsed/refractory lymphoid malignancies, both as a monotherapy and in combination with zanubrutinib.

Prelude Therapeutics announced encouraging clinical data for its SMARCA2 degrader programs and a solid cash position extending into 2026.

Prelude Therapeutics presented updated clinical data from its PRT3789 trial and preclinical data on its novel SMARCA2/4 dual degrader antibody conjugate program at the 36th EORTC-NCI-AACR Symposium.

Prelude Therapeutics reports encouraging initial clinical activity and a tolerable safety profile for its SMARCA2 degrader, PRT3789, in a Phase 1 trial, showing objective responses in some patients with SMARCA4-mutated cancers.

Prelude Therapeutics has released an abstract detailing positive early clinical results for their novel SMARCA2 degrader, PRT3789, in patients with advanced solid tumors and SMARCA4 mutations.

Prelude Therapeutics reported its second quarter 2024 financial results, highlighted by clinical progress with its SMARCA2 degraders and CDK9 inhibitor, and a collaboration with Merck.

Prelude Therapeutics held its 2024 Annual Meeting of Stockholders, electing two Class I Directors and ratifying Ernst & Young LLP as its independent auditor for the fiscal year ending December 31, 2024.

Prelude Therapeutics is progressing its SMARCA2 degrader programs, including both intravenous and oral candidates, and expects initial clinical proof-of-concept data in the second half of 2024.

Prelude Therapeutics has amended its previous 8-K filing to include details about stock options granted to its Interim Chief Financial Officer, Bryant D. Lim.

Prelude Therapeutics announced its Q1 2024 financial results, highlighting progress in clinical trials for its lead drug candidates and strengthening its leadership team.

Prelude Therapeutics has announced the departure of its Chief Financial Officer, Laurent Chardonnet, and the appointment of its Chief Legal Officer, Bryant D. Lim, as interim CFO, effective April 8, 2024.